Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to a...
Main Authors: | Teh, L. K., Langmia, I. M., M. H., Fazleen Haslinda, Ngow, Harris Abdullah, Roziah, M. J., Harun, R., Zakaria, Z. A., Salleh, M. Z. |
---|---|
Format: | Article |
Language: | English |
Published: |
Blackwell Publishing
2011
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/5105/ http://irep.iium.edu.my/5105/ http://irep.iium.edu.my/5105/2/Cyp2c9_and_VKROC.pdf |
Similar Items
-
Lack of correlation between INR and warfarin dose: a role of pharmacogenotyping of CYP2C9*3 and VKORC1 for anticoagulation
by: Salleh, Mohd Zaki, et al.
Published: (2009) -
VKORC1 Haplotypes in patients treated with warfarin
by: Beshna, E, et al.
Published: (2010) -
CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia
by: Ngow, Harris Abdullah, et al.
Published: (2009) -
Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study
by: Ngow, Harris Abdullah, et al.
Published: (2008) -
Agarwood classification based on odor profile using intelligent signal processing technique
by: M. S., Najib
Published: (2012)